Experience

The University of Texas at Austin, College of Pharmacy

• United States
• Higher Education
• 1 - 100 Employee

• • Sep 2022 - Present

  - Development of proteolysis-targeting chimeras (PROTACs) for degradation of MELK in HeLa cells, utilizing expertise in molecular biology and chemical biology techniques.- Identification and optimization of covalent inhibitors targeting MELK, leveraging knowledge of protein structure and mechanism of action.

• • Sep 2016 - Aug 2022

  - Design and synthesis of potent and selective compounds targeting MELK, with demonstrated efficacy in preclinical models of TNBC.



KIST(Korea Institute of Science and Technology)

• South Korea
• Research Services
• 700 & Above Employee

• • Mar 2015 - Mar 2016

  -Development of novel heat shock protein 90 (HSP90) inhibitors for anticancer agents.-Development of novel kinase inhibitors for anticancer agents.

• • Mar 2008 - Mar 2015

  -Development of novel heat shock protein 90 (HSP90) inhibitors for anticancer agents.-Development of new anti-hepatitis C virus (HCV) agents for targeting NS5A.-Synthesis of new PreQ1 riboswitch regulators and binding studies using NMR.-Development of novel kinase inhibitors for anticancer agents.-Docking studies of new oxazolidinone antibacterials on the ribosomal PTC site.-Study of the development of new reactions using indium metal.-Synthesis of novel T-type calcium channel blockers with antinociceptive effects in a neuropathic pain model. Show less